Trial · NCT07911553
A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5
NCT07911553, Phase 3, Not yet recruiting, AstraZeneca
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5. Trials, record NCT07911553. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07911553
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5
- NCT number
- NCT07911553
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 1,200 participants, estimated
- Lead sponsor
- AstraZeneca
- Conditions
- Large B-cell Lymphoma
- Interventions
- Surovatamig, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Polatuzumab vedotin
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression free survival (PFS) as assessed by Blinded Independent Central Review (BICR) | Up to 10 years | The PFS is defined as the time from randomisation to the first occurrence of disease progression as determined by an Independent Review Committee (IRC), or death from any cause, whichever occurs first. |
| Secondary | Overall survival (OS) | Up to 10 years | The OS is defined as the time from randomisation to death due to any cause. |
| Secondary | PFS as assessed by the investigator | Up to 10 years | The PFS is defined as the time from randomisation to the first occurrence of disease progression as determined by the investigator, or death from any cause. |
| Secondary | Event-free survival efficacy (EFSeff) | Up to 10 years | The EFSeff is defined as the time from randomisation to the first occurrence of disease progression, relapse, death from any cause, initiation of new antilymphoma treatment for an efficacy-related reason. |
| Secondary | Overall response (OR) rate | Up to 10 years | The OR is defined as the percentage of participants who achieve a partial response (PR) or complete response (CR), as assessed by the investigator and IRC separately. |
| Secondary | CR rate | Up to 10 years | The CR is defined as the percentage of participants who achieve a CR, as assessed by the investigator and IRC separately. |
| Secondary | Duration of response (DoR) | Up to 10 years | The DoR is defined as the time from the first documented OR to disease progression or death from any cause, whichever occurs first, as assessed by IRC. |
| Secondary | Duration of Complete Response (DOCR) | Up to 10 years | The DOCR is defined as the time from the first occurrence of a documented CR to disease progression, or death, whichever occurs first, as assessed by IRC. |
| Secondary | Disease-free survival (DFS) | Up to 10 years | The DFS is defined as the time from a documented CR at the end of treatment to disease progression or death from any cause, whichever occurs first, as assessed by the investigator and IRC separately. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07911553
GET https://conductscience.org/api/trials/v1/NCT07911553/registered